7.760USD-31.63%Mkt Cap: 144.70M USDP/E: —Last update: 2026-05-26
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of N…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap144.70M USD
Enterprise Value67.16M USD
Revenue (TTM)—
Gross Profit-70.09M USD
Net Income (TTM)-78.54M USD
Revenue/Share—
Last Price7.760 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees36
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINLU1829218749
Valuation
P/E (Trailing)—
P/E (Forward)-2.27
PEG—
EV/EBITDA-0.75
EV/Revenue—
P/S—
P/B1.62
EPS (TTM)-5.74
EPS (Forward)-5.08
52W Range
6.7208% of range20.56
52W High20.56 USD
52W Low6.720 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.24%
ROA-46.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.49M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield—
Net Debt-137.01M USD
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.01
Current Ratio7.92
Quick Ratio7.62
Book Value/Sh7.122 USD
Cash/Share7.792 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)38.40 USD
Target Range17.00 USD – 54.00 USD
# Analysts10
Ownership
Shares Out.18.53M
Float12.74M
Insiders0.57%
Institutions71.95%
Short Interest
Short Ratio5.3d
Short % Float9.21%
Short % Out.7.94%
Shares Short1.41M
Short (prev mo.)1.21M
Technical
SMA 509.999 (-22.4%)
SMA 20010.36 (-25.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)418.95K
Avg Vol (10d)296.59K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—